ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Jyong Biotech (MENS)
Jyong Biotech stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$1.77▲ 0.00%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
47%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Jyong Biotech in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Jyong Biotech
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Jyong Biotech a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $1.57 and $1.95; in 9 out of 10, between $1.30 and $2.37. Estimated annual volatility is 66%.
Key numbers
- Market cap
- $166M
- Revenue (12 months)
- $0.0M
- Return on equity
- 18.8%
- Free cash flow (12 months)
- $4.4M
- Beta
- 0.00
What this means
ATLAS does not publish a fair value for MENS right now, but it does show its odds of rising: close to a coin flip.
Its beta is 0.00: it tends to move less than the market.
About the company
Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing and commercializing plant-derived medicines for urinary system diseases.
Want to see everything about Jyong Biotech?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Jyong Biotech do?
Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing and commercializing plant-derived medicines for urinary system diseases.
What is the chance MENS goes up next month?
47%: close to a coin flip. In half of the simulated outcomes, MENS ends the month between $1.57 and $1.95.
How big is Jyong Biotech and what is its P/E ratio?
Jyong Biotech's market capitalization is $166M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is MENS?
ATLAS estimates annual volatility at 66%. In a typical month, half of the outcomes end between $1.57 and $1.95.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer